Literature

Prescott Group staff members' contributions to the medical literature include the following publications:

Depression

A phase 3, double-blind, randomized, placebo-controlled study of vilazodone in adolescents with major depressive  disorder.

Durgam S, Chen C, Migliore R, et al. Paediatr Drugs. 2018;20(4):353-363.

Dermatology

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).

Lebwohl M, Blauvelt A, Paul C, et al. J Am Acad Dermatol. 2018;79(2):266-276.e5.

HIV

Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-PI.

Arribas JR, DeJesus E, van Lunzen J, et al. HIV Clin Trials. 2017;18(3):118-125.

Epilepsy

Deconstructing tolerance with clobazam: Post hoc analyses from an open-label extension study.

Gidal BE, Wechsler RT, Sankar R, et al. Neurology. 2016;87(17):1806-1812.

Hypertension

Rationale for nebivolol/valsartan combination for hypertension: Review of preclinical and clinical data.

Giles TD, Cockcroft JR, Pitt B, Jakate A, Wright HM. J Hypertens. 2017;35(9):1758-67.

Migraine

AVP-825: A novel intranasal delivery system for low-dose sumatriptanpowder in the treatment of acute migraine.

Silberstein S. Expert Rev Clin Pharmacol. 2017;10(8):821-32.

Respiratory

Effect of roflumilast and inhaled corticosteroid/long-acting beta2-agonist on chronic obstructive pulmonary disease exacerbations (RE2SPOND). A randomized clinical trial.

Martinez FJ, Rabe KF, Sethi S, et al. Am J Respir Crit Care Med. 2016;194(5):559-67.

Schizophrenia

Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: A randomised, double-blind, controlled trial.

Németh G, Laszlovszky I, Czobor P, et al. Lancet. 2017;389(10074):1103-1113.

Tardive Dyskinesia

KINECT 3: A phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia.

Hauser RA, Factor SA, Marder SR, et al. Am J Psychiatry. 2017;174(5):476-484.

Urology

Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial.

Kleinmann N, Matin SF, Pierorazio PM, et al. Lancet Oncol. 2020;21(6):776-785.

Women's Health

Ulipristal acetate for treatment of symptomatic uterine leiomyomas: A randomized controlled trial.

Simon JA, Catherino W, Segars JH, et al. Obstet Gynecol. 2018;131(3):431-439.

Offices

205 N. Michigan Avenue
Suite 3400

Chicago, Illinois 60601

Telephone

312-528-3900

Fax

312-528-3901

© 2020 Prescott Medical Communications Group